Mavericks Wanted
When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here—but if it sparks excitement…read on.
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease and develop life-changing medicines for patients with unmet needs as fast as humanly possible.
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask “why not?” and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work
Affiliate Overview
ML Bio, an affiliate within BridgeBio Pharma, is developing BBP-418 (ribitol), an investigational oral therapy for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare genetic neuromuscular disease caused by mutations in the FKRP gene. BBP-418 is designed to address the underlying disease biology by supplying ribitol to support proper glycosylation of α-dystroglycan, which is critical for muscle integrity and function. The program has received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency, as well as Fast Track and Rare Pediatric Disease Designations from the U.S. FDA. Topline interim results from the Phase 3 FORTIFY study have been publicly reported and support the ongoing clinical development of BBP-418. BBP-418 continues to be evaluated in global registrational clinical studies with the intent to bring a potential therapy to patients affected by this serious rare disease.
What You’ll Do
Responsibilities
Where You’ll Work
This is a U.S.-based remote role that will generally require up to three visits per year, or as needed, to our San Francisco office.
Who You Are
Rewarding Those Who Make the Mission Possible
We have high expectations for our team members and ensure that those working hard for patients are rewarded and supported.
Financial Benefits
Health & Wellbeing
Skill Development & Career Paths
#LI-NT1
BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 20+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs. Our focus on scientific excellence and rapid execution aim to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe. To learn more about our story and company culture, visit us at https://bridgebio.com
Please mention you found this job on AI Jobs. It helps us get more startups to hire on our site. Thanks and good luck!
Understand the required skills and qualifications, anticipate the questions you may be asked, and study well-prepared answers using our sample responses.
Senior Director Q&A's